Key Takeaways
Eli Lilly (LLY) reported Q4 revenue of $19.3B (+43% YoY) and non-GAAP EPS of $7.54 vs. $6.96 consensus, driven by GLP-1 drugs Mounjaro ($7.4B, +110% YoY) and Zepbound ($4.3B, +123% YoY). Full-year 2025 revenue: $65.2B (+45%). 2026 guidance: $80–83B revenue, non-GAAP EPS $33.50–35.
Johnson & Johnson (JNJ) posted Q4 sales of $24.6B (+9.1% reported; +7.1% operational), adjusted EPS $2.46 in line with forecasts. Full-year 2025 revenue: $94.2B (+6%). 2026 guidance: ~$100B operational sales, adjusted EPS ~$11.53.
Market Reaction: LLY shares rose ~5–8% post-earnings on strong beats and guidance; JNJ dipped 1–2% despite revenue strength, reflecting in-line EPS.
LLY provides high-growth exposure to obesity/diabetes; JNJ offers diversified stability across pharmaceuticals and MedTech.
Earnings Context
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion. Comparing the two illustrates a trade-off: LLY offers concentrated blockbuster momentum and rapid growth, while JNJ delivers stable, broad-based performance with resilient cash flows.
Eli Lilly (LLY) Q4 2025 Highlights
Revenue: $19.3B (+43% YoY, vs. ~$17.9B consensus)
Non-GAAP EPS: $7.54 (+42% YoY, beat $6.96–7.20)
Key drivers: Mounjaro $7.4B (+110% YoY), Zepbound $4.3B (+123% YoY)
Volume growth: 46% for key drugs; minor 5% price declines
Full-year revenue: $65.2B (+45%)
Guidance 2026: Revenue $80–83B, non-GAAP EPS $33.50–35 (~25% sales growth)
Market response: Shares gained ~5–8% post-release
Johnson & Johnson (JNJ) Q4 2025 Highlights
Revenue: $24.6B (+9.1% reported; +7.1% operational, beat ~$24.1B)
Adjusted EPS: $2.46, in line with consensus
Segment drivers: Innovative Medicines +5.3% operational (10% Q4), led by DARZALEX, TREMFYA, CAPLYTA; MedTech +5.4%
Full-year revenue: $94.2B (+6%)
2026 guidance: Operational sales ~$100B, adjusted EPS ~$11.53
Market response: Shares dipped 1–2% post-earnings
Insight: LLY’s growth trajectory dwarfs JNJ’s operational expansion, driven by concentrated blockbuster therapies, while JNJ provides multi-segment stability and predictable cash flows. LLY carries higher P/E, reflecting growth premium; JNJ offers defensive reliability and dividends.
AI Trading Bot Perspective
Tickeron’s Trend Trader for Beginners Strategy (60-min TA) highlights LLY’s momentum as favorable in short- to medium-term trends, driven by earnings beats and guidance, while JNJ’s steadier growth signals lower volatility strategies for defensive positioning. The bot emphasizes trend alignment, stop-loss discipline, and historical pattern recognition for both names.
Conclusion: LLY currently leads probabilistically in bull-market scenarios due to strong near-term earnings momentum and blockbuster pipeline growth, whereas JNJ suits investors prioritizing diversification, MedTech exposure, and stable dividend income.
Disclaimers and Limitations
Be on the lookout for a price bounce soon.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Oscillator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +1.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 52 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor